Form 4: BioMarin CFO Brian Mueller Reports Stock Transactions

Brian Mueller, EVP and CFO of BioMarin Pharmaceutical Inc., reports the acquisition and disposal of company stock and stock options.

Summary

• Brian Mueller, the EVP and Chief Financial Officer of BioMarin Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 14, 2025, Mueller disposed of 18,497 shares of Common Stock at a price of $69.44.
• On March 17, 2025, Mueller acquired 16,640 shares of Common Stock at a price of $0 related to restricted stock units.
• Following these transactions, Mueller beneficially owns 83,141 shares of Common Stock.
• Mueller also acquired 38,590 stock options with an exercise price of $71.55 on March 17, 2025, which vest over time starting March 17, 2026, and expire on March 16, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions. The acquisition of restricted stock units and options is a positive sign, but the disposal of shares tempers the overall sentiment.

Positives

• The acquisition of restricted stock units and stock options suggests continued alignment of the CFO's interests with the company's long-term performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the stock options suggests a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to align management's interests with shareholder value.
• The vesting schedule of the options (12/48th on the first anniversary, then 1/48th monthly) is a typical structure for incentivizing long-term performance.
• Comparing the size of the grant to those of peers at companies like Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN) would provide context on the relative magnitude of the compensation.

Stakeholder Impact

• Shareholders may view the transactions as an indication of management's confidence (or lack thereof) in the company's future performance.
• Employees may see the stock option grants as a positive sign of potential future gains.

Key Dates